2(b) or Not 2(b): FDA Releases New Guidance on Determining Whether to Submit an ANDA or 505(b)(2)

In the drama of pharmaceutical development, the question of whether to submit an Abbreviated New Drug Application (ANDA) under section 505(j) or a 505(b)(2) application can be a source of angst for sponsors — a choice with consequences that go beyond time and filing fees.

In May 2019, the US Food and Drug Administration (FDA) issued its final guidance, Determining Whether to Submit an ANDA or a 505(b)(2) Application, offering a framework for navigating this pathway determination. Now, in August 2026, FDA has published a revised draft guidance that updates and expands upon its predecessor. Like any good sequel — or perhaps Act II — the 2026 draft retains the original’s essential architecture while introducing substantive refinements worth noting when making the important decision of the proper framework for your generic application.

What Is in a Name Change? Substantive Revisions in the 2026 Draft

While Shakespeare noted in another of his works that a rose by any other name might smell as sweet, nomenclature matters enormously in the regulatory context — and FDA’s 2026 draft makes several changes that alter the analytical landscape in meaningful ways. While FDA updated the many cross references to regulations and guidances that have changed since 2019, the following are some of the more noteworthy revisions.

Discontinued Drug Products and Duplicates

The most substantial expansion appears in Section IV.A.1, where the 2026 draft adds two critical new scenarios for situations where comparative bioequivalence studies cannot be conducted because the Reference Listed Drug (RLD) has been discontinued and no other suitable reference standard is available. Under the first scenario, FDA now recommends that applicants consider “alternate methods to establish bioequivalence” and contact the Office of Generic Drugs (OGD) to discuss. Under the second — where FDA determines no acceptable alternate bioequivalence methods exist — a prospective applicant may consider a 505(b)(2) application, though FDA cautions that “there may be limitations on when it would be appropriate.” If FDA subsequently identifies acceptable alternate bioequivalence (BE) methods, it will still consider the product eligible for 505(j) and refuse to file a 505(b)(2). However, if the RLD moves from the Discontinued to Active Section before submission, the 505(b)(2) route is generally foreclosed.

New Waivers

Section IV.B.3.a introduces a significant new discussion of waivers under 21 CFR 314.99(b). FDA may now waive certain inactive ingredient requirements — specifically, those in 21 CFR 314.94(a)(9)(iii) and (iv) — provided statutory safety requirements are met. The guidance offers a concrete example: it may be appropriate for FDA to grant a waiver permitting a Q1 or Q2 difference in pH adjuster(s) for generic products intended for parenteral, ophthalmic, or otic use. This provision cross-references a November 2025 guidance on pH adjuster waivers, signaling that FDA’s waiver toolkit is expanding.

Call Out to FDA Before You Take the Leap

One of the most notable shifts between the two guidances involves FDA’s recommendation that prospective applicants contact the Agency when pathway determinations are ambiguous. The 2019 guidance included such advice, but it appeared primarily in contextualized discussions. The 2026 draft, by contrast, introduces this recommendation far earlier and more prominently, and repeatedly. FDA is inviting the conversation to happen before the commitment, not after a refuse-to-file letter.

A Change of Temperament: From Suggestion to Direction

If the 2019 guidance was a courteous suggestion — “We recommend that a prospective ANDA applicant …” — the 2026 draft speaks with the more assured voice of experience. The language shifts from hedged recommendations to more direct instruction: “A prospective applicant … should contact OGD.” The conditional gives way to the imperative. Less “you might consider”; more “you should do.” This tonal shift is likely neither accidental nor merely stylistic, but more a result of seven years of experience where applicants’ incorrect choices sapped the resources of both the applicants and the Agency.

Key Takeaways: The Curtain Call

As our players exit the stage, four practical lessons emerge from FDA’s 2026 revisions:

1. Engage Early: FDA’s early and emphatic insistence on pre-submission dialogue is not mere courtesy — it is a procedural shield. Sponsors who contact the Agency before filing materially reduce the risk of refuse-to-file actions and pathway mischaracterization. For regulatory counsel, building pre-submission meetings into the development timeline is no longer a best practice; it is essential risk management.

2. The Discontinued Drug Product Opportunity: The expanded duplicates section creates new analytical opportunities when an RLD appears on the Discontinued list. Sponsors must assess whether alternate BE methods exist and whether FDA agrees — since FDA retains the final word on eligibility. Intellectual property and litigation counsel should note that the pathway available to a generic product may shift based on Orange Book status changes, with implications for patent certification and exclusivity strategies.

3. Waivers Expand the ANDA Toolkit — Within Limits: The new waiver discussion in Section IV.B.3.a means that certain formulation differences that previously might have forced a 505(b)(2) filing could now be accommodated within the ANDA pathway. However, FDA is clear that waivers do not relax statutory approval requirements. For sponsors, this warrants early identification of potential waiver candidates and proactive engagement with FDA.

2(b) or not 2(b)

In the end, the question remains one that each sponsor must answer based on its unique product, scientific considerations, and strategic posture. But FDA’s 2026 revisions provides additional considerations for reaching that answer. The decision to proceed with an ANDA or 505(b)(2) application has dramatic impact on a company’s development strategy and on the resulting litigation, though not as dramatic as the decisions made by Shakespeare’s ill-fated protagonists. And here, FDA is inviting a conversation before any final decisions are made.